AzTrials
AzTrials

NeurosciencesEarly Phase 1NCT03944954

Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults

A Early Phase 1 study testing Marinol 10Mg Capsule TMS Real in people with Neurosciences and Substance-Related Disorders, run by Michael J. Wesley, PhD at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Emerging adults are a particularly vulnerable group for experiencing the immediate and potentially lifelong negative impacts of habitual cannabis use, and trends suggest that cannabis use disorder (CUD) will soon escalate in this population. Read more about this study

Who is it for?
Ages 18 to 34 years
What is being tested?
Marinol 10Mg Capsule TMS Real
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
66 participants
Where
1 siteUnited States
Study dates
15 Jul 2017to 13 Dec 2023
Phase
Early Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 34 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Habitual cannabis use problems
  • Body Mass Index ≤30

Who cannot join

  • Past or current serious physical or mental health
  • Sesame seed oil allergy
  • Irregular health issues identified by the Study Physician
  • Standard magnetic resonance imaging and transcranial magnetic stimulation exclusion criteria (e.g., metal implants, history of epilepsy, etc.)
  • Lack of affective form of birth control (females)
  • Pregnancy (females)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Neurobehavioral Systems Lab of the University of Kentucky College of Medicine

    Lexington, Kentucky, 40507

Other trials in United States

About this study

Emerging adults are a particularly vulnerable group for experiencing the immediate and potentially lifelong negative impacts of habitual cannabis use, and trends suggest that cannabis use disorder (CUD) will soon escalate in this population. The proposed research will combine clinical pharmacology, non-invasive brain stimulation, and neuroimaging techniques to establish the brain mechanisms of cannabinoid-impaired decision-making processes in emerging adults with CUD. Results from this project will inform CUD prevention/treatment efforts in this high-risk group and address a growing public health concern.

Read the detailed description

This mentored career development award (K01) will enable Dr. Michael J. Wesley to achieve his long-term goal of becoming an independent investigator with a clinical research program examining cannabis use disorder (CUD) in emerging adults, which is a current NIDA funding priority. Dr. Wesley is a new Assistant Professor at the University of Kentucky (UK) College of Medicine. The activities proposed in this award build on Dr. Wesley's background in neuroimaging and drug abuse research and will allow him to accomplish these specific short-term objectives: Become an expert in (1) clinical pharmacology and (2) non-invasive brain stimulation research, and enhance/develop his (3) knowledge of the responsible conduct of research, (4) skills for scientific communication and grant writing, and (5) ability to manage an independent research program. UK has numerous faculty and projects focused on drug abuse research and is an ideal environment for Dr. Wesley to successfully complete this award. Dr. Wesley has assembled a stellar mentoring team consisting of Dr. Josh Lile (Mentor), who runs a successful NIH-funded clinical pharmacology research program at UK and Drs. Mark George (Co-Mentor) and Colleen A. Hanlon of the Brain Stimulation Laboratory at the Medical University of South Carolina, Together they will guide and oversee Dr. Wesley's training in clinical pharmacology, brain stimulation, and scientific communication and grant writing. Dr. Wesley has proposed to engage in a series of formal classes, lab exchanges, and research seminars/meetings that will assist him in accomplishing the objectives of this award.

The proposed research project is novel, innovative, and rigorous. It will combine the acute administration of Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, with brain stimulation and neuroimaging to examine the role of the dorsal lateral prefrontal cortex (DLPFC) and connected brain areas in drug-impaired decision-making processes. Specifically, transcranial magnetic stimulation (TMS) will be used to raise or lower DLPFC functionality following the administration THC in randomized, double-blind, placebo- and sham-controlled experiments.

Aim 1 will test the hypotheses that excitatory TMS (raising DLPFC functionality) will attenuate the impairing effects of THC on study outcomes.

Aim 2 will test the hypotheses that inhibitory TMS (lowering DLPFC functionality) will enhance the impairing effects of THC on study outcomes.

Results from this project will improve the investigator's understanding of the mechanisms involved in cannabis-impaired decision-making, which will inform CUD management and address a growing public health concern.

Being tested
Placebo TMS Sham, Marinol 10Mg Capsule TMS Sham, Marinol 30Mg Capsule TMS Sham, Placebo TMS Real, Marinol 10Mg Capsule TMS Real
Medical subject headings
Substance-Related Disorders, Mental Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo TMS ShamDevice

    Also called Placebo, Sham TMS

    Individuals will receive placebo dose and sham TMS.

  • Marinol 10Mg Capsule TMS ShamDrug

    Also called 10mg THC, Sham TMS

    Individuals will receive 10mg dose and sham TMS.

  • Marinol 30Mg Capsule TMS ShamDrug

    Also called 30mg THC, Sham TMS

    Individuals will receive 30mg dose and sham TMS.

  • Placebo TMS RealDevice

    Also called Placebo, Real TMS

    Individuals will receive placebo and real TMS.

  • Marinol 10Mg Capsule TMS RealOther

    Also called 10mg THC, Real TMS

    Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

  • Marinol 30Mg Capsule TMS RealOther

    Also called 30mg THC, Real TMS

    Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

Study groups in NCT03944954
Study groupRoleWhat they receive
Excitatory TMSExperimentalIndividuals assigned to this group will receive excitatory (real and sham) TMS in combination with 0, 10, and 30mg THC.
Receives: Device: Placebo TMS Sham; Drug: Marinol 10Mg Capsule TMS Sham; Drug: Marinol 30Mg Capsule TMS Sham; Device: Placebo TMS Real; Other: Marinol 10Mg Capsule TMS Real; Other: Marinol 30Mg Capsule TMS Real
Inhibitory TMSExperimentalIndividuals assigned to this group will receive inhibitory (real and sham) TMS in combination with 0, 10, and 30mg THC.
Receives: Device: Placebo TMS Sham; Drug: Marinol 10Mg Capsule TMS Sham; Drug: Marinol 30Mg Capsule TMS Sham; Device: Placebo TMS Real; Other: Marinol 10Mg Capsule TMS Real; Other: Marinol 30Mg Capsule TMS Real

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Alpha Learning Rate

    In a Probabilistic Reinforcement Learning Choice (PRLC) task, two stimuli are presented and choosing either could result in a monetary reinforcer, but the reinforcement probabilities of the stimuli differ, and change throughout the task. Individuals attempt to optimize choices according to learned probabilities and track changing probabilities over time.

    PRLC performance allows mathematical modeling of trial-by-trial data under "real-world" uncertainty and yields computational parameters, such as the learning rate. Choice data were analyzed using a Rescorla-Wanger learning model with an alpha learning rate, beta inverse temperature, and perseveration global parameters. Model-derived learning rates are indicative of an individual's ability to learn from previous choice outcomes to update future decision-making. For this task, learning rates range from 0-1 with lower values indicative of more optimal learning.

    Measured: Measure collected at 2 time points: Baseline (0HR) and Post TMS Administration (3HR)

  2. Self-Report Subjective "High"

    A Visual Analogue Scale (VAS) was used to measure the acute subjective effects of THC at varying doses (0mg, 10mg, 30mg). Responses are made for VAS items along a 100-unit scale anchored on the extremes by "Not At All" (0) and "Extremely" (100) with a higher score meaning more of the effect. Participants were instructed to select "Not At All" (0) for all baseline (0HR) measures. Post-TMS administration (real or sham), participant self-reported their subjective "high" on the VAS with higher values indicating a more intense sensation of "high".

    Measured: Measured 2 times: Baseline (0HR) and 3 hours (3HR) after capsule administration on each drug condition (0mg, 10mg, 30mg)

  3. Elasticity of Demand

    Elasticity of Demand was measured by the Cannabis Purchase Task (CPT) where participants are asked how many "hits" of cannabis they would consume at 16 different price points in ascending order ($0-$140). Higher elasticity values indicate a greater sensitivity to changing price points resulting in a reduced demand for "hits" of THC at increasing price points.

    Measured: Measured 2 times: Baseline (0HR) and Post-TMS (3HR) after THC administration on each drug condition (0mg, 10mg, 30mg).

  4. Working Memory Performance

    Working memory (WM), the ability to hold a finite amount of information for a set amount of time, is measured by the N-Back task. Here, participants were presented with a sequence of letters and must indicate when the letter currently being viewed matches the one from N steps earlier in the sequence. The load factor "N" is adjusted between 0, 1, and 2 to adjust the difficulty of the task (0-Back = no WM load, 1-Back = minimal WM load, 2-Back = greater WM load) where a higher score means better memory performance. Outcomes are reported as the Total Accuracy Percentage (Correct Choices/Total Choices) x 100%

    Measured: Measured 2 times: Baseline (0HR) and Post-TMS (3HR) after THC administration on each drug condition (0mg, 10mg, 30mg).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2019
  2. Study start15 Jul 2017
  3. Primary completion13 Dec 2023
  4. Study completion13 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be assigned to either excitatory or inhibitory TMS treatment arms. All individuals will receive multiple doses of oral THC (0, 10 and 30mg) and TMS (real or sham).
Masking
Single blind
Who is masked
Investigator
Enrolment
66 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03944954
Sponsor's protocol ID
K01DA043652
Other IDs
K01DA043652
Status last verified
Mar 2024
First submitted
6 May 2019
Last updated
5 Apr 2024
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Marinol 10Mg Capsule TMS Real in people with Neurosciences and Substance-Related Disorders, run by Michael J. Wesley, PhD at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Apr 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Alpha Learning Rate (time frame: Measure collected at 2 time points: Baseline (0HR) and Post TMS Administration (3HR)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in